Biocompatibility Testing in Medical Device 2024 Conference

NAMSA invites you to join us at Biocompatibility Testing in Medical Devices 2024 Conference on March 21-22 in Munich, Germany. The Biocompatibility Testing in Medical Devices Conference functions as a crucial platform for the exploration of the latest challenges, novel applications, innovations, and trends within the Medical Devices Industry. It provides an opportunity for attendees to engage in stimulating discussions, gain fresh insights, and establish valuable connections. Throughout the two days, the aim is to foster collaboration and empower progress. The presence of participants is integral to the mission of shaping the future of biocompatibility testing. Together, they will advance the standards of excellence in the field.

NAMSA invites you to join the upcoming Biocompatibility Testing in Medical Devices 2024 Conference. Our distinguished speaker, Silke Laugeois, Principal Biological Safety Scientist, will present on “Understanding updates of ISO 10993-17:2023 for assessing Leachable Substances“. This event serves as a vital platform for exploring the latest challenges, novel applications, innovations, and trends within the Medical Devices Industry. It offers an opportunity to engage in stimulating discussions, gain fresh insights, and establish valuable connections. Over these two days, the conference aims to foster collaboration and empower progress. Your presence is integral to our mission of shaping the future of biocompatibility testing, and together, we will advance the standards of excellence in the field.

Speaker

Silke Laugeois, Principal Biological Safety Scientist

Silke joined NAMSA in 2019 as a consultant, after performing biological evaluations for BIOTRONIK, a German cardiovascular device manufacturer, for two years. Over the years, she has provided numerous Biological Evaluation Plans and Reports, Risk Assessments, Gap Analyses, Expert Reports as well as Toxicological Risk Assessments for all type of medical devices in compliance with the ISO 10993 series, ISO 14971, ISO/TS 21726, EU MDR, U.S. FDA, as well as other regional standards.

She has a PhD in Molecular Genetics, a strong academic/research background and performed preclinical in vivo and in vitro studies within the biomedical research field of bone substitutes for 4 years prior to supporting manufacturers’ documentation on the biological safety of marketed and new medical devices.